Placebo | Vildagliptin | |
---|---|---|
N | 6 | 9 |
Age (years) | 60 (39–67) | 64 (42–67) |
BMI (kg/m2) | 32 (26–35) | 32 (27–34) |
Female (%) | 17% | 22% |
Duration DM (years) | 5.5 (1–23) | 6.0 (2–15) |
Prior medication | ||
metformin/SU/TZD/other (%) | 100/67/0/33% | 100/89/11/22% |
Diabetic complications | ||
any microvascular complication (%) | 17% | 33% |
any macrovascular complication (%) | 0% | 33% |
BP (syst/diast in mmHg) | 128/78 | 126/73 |
HbA1c at start of the trial (mmol/mol) | 64 (53–74) | 62 (57–73) |
(%) | 8.0 (7.0-8.9) | 7.8 (7.4-8.8) |
SD of glucose values (variability) at start of trial | 1.8 (1.0 -2.7) | 1.7 (1.2 – 2.6) |